An accountant by training, Bruce has spent over two decades working in the life sciences and pharmaceutical industry. Bruce has spent the last 16 years of his career at Liminal BioSciences Inc., a former NASDAQ listed company focused on the development of small molecule therapeutics. Bruce was appointed as CEO of Liminal in 2020 but prior to that he held various senior executive positions across the organization including Chief Operating Officer and Group Chief Financial Officer. Prior to joining Liminal, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company. Bruce brings a proven track record of success in strategic acquisitions, raising debt and equity financing, clinical development, project management, CMC and business development to his new role of CEO at Caledon Bioscience Inc. Bruce is a graduate of Heriot-Watt University where he earned a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Directors. He is also the Interim Chair of the Board of Porton Biopharma Limited, is past President of the Institute of Chartered Accountants of Scotland and is the current Chair of Court at Heriot-Watt University.